ClinicalTrials.gg
CompletedNCT04971161Updated Dec 4, 2025

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of CVU (Phase IIb)

A Phase 2 interventional study of allo-APZ2-CVU and Placebo in Skin Ulcer Venous Stasis Chronic, sponsored by RHEACELL GmbH & Co. KG. Completed at 38 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by RHEACELL GmbH & Co. KG · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Varicose Ulcer with a site in Germany — 3 open to participants now, 5 under way, 2 of them phase 3. Varicose Ulcer · Germany.

Enrollment
10th of 21
159 · median 152
Started
2021
with 2 others
Phase 2
2 of 24
none open now
Registered
17th of 24
by date
Lead sponsor
4 of 24
RHEACELL GmbH & Co. KG

Among the 24 studies in Varicose Ulcer with a site in Germany, this one is the 10th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2021, is one of 2 in phase 2, and was the 17th registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 75 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

3 of the 24 studies in Varicose Ulcer with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Varicose Ulcer with a site in Germany, or all of them as a file.
02

Study summary

The aim of this clinical trial is to investigate the efficacy (by monitoring the wound size reduction of CVUs) and safety (by monitoring adverse events [AEs]) of three dose groups of the investigational medicinal product (IMP) allo-APZ2-CVU, topically administered on target wounds of patients with CVU compared to placebo.

Read the detailed description

This is a randomized, placebo-controlled, double-blind, dose-ranging, multicenter, phase IIb clinical trial to investigate the efficacy and safety of the IMP allo-APZ2-CVU on wound healing in patients with therapy-resistant CVU. The allogeneic IMP allo-APZ2-CVU contains skin-derived ABCB5-positive dermal mesenchymal stromal cells isolated from skin tissue of healthy donors and stored in a donor cell bank.

Patients will be randomized to be treated with allo-APZ2-CVU (dose 1, dose 2, dose 3) or placebo (50 patients per dose group). The patients will undergo treatment with the IMP on Day 0 (V3) and will be followed up for efficacy for 18 weeks (V4 until V14). Two safety follow-up visits will be performed at Month 6 (V15) and Month 10 (V16). An additional visit (V17) will be performed to follow up on target wounds of all patients who reached the primary endpoint (i.e. wound was closed at V13 and V14) at Month 16 (at least).

The wound healing process will be documented by standardized photography. The wound size measurement will start at the first Screening Visit (V1) and will be measured at each following on-site visit.

Pain will be assessed using a numerical rating scale and quality of life will be investigated with standardized and validated questionnaires.

03

Conditions studied

  • Skin Ulcer Venous Stasis Chronic

Keywords

  • Chronic Venous Ulcer
  • ABCB5
  • Allogeneic
  • Dermal mesenchymal stromal cells
  • varicose ulcer
  • skin ulcer
  • advanced therapy medicinal product
  • somatic cell therapy
  • phase IIb
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients at least 18 years old;
  2. Chronic venous leg ulcer (as defined by the current AWMF guidelines: therapy-resistant ulcer that shows no tendency to heal within 3 months despite of optimal phlebological therapies or has not fully healed within 12 months) at lower leg and/or ankle region and has not been present longer than 15 years, diagnosed by doppler or duplex sonography, ankle brachial index (ABI, 0.9-1.3), physical examination and dermatological review;
  3. Wound size of target ulcer between 1 and 50 cm² measured by a standardized photography at the screening visit;
  4. If patients have 2 or more ulcers at the same extremity, the target ulcer has to be separated by a minimum bridge of 1 cm of epithelialized skin from other ulcers (the largest ulcer should be the target ulcer, if not decided otherwise at discretion of the investigator; the target ulcer is defined at Visit 1);
  5. between 15 and 50 kg/m²;
  6. Patients understand the nature of the procedure and are providing written prior to any clinical trial procedure;
  7. Women of must have a negative blood pregnancy test at Visit 1;
  8. Women of childbearing potential and their partner must be willing to use highly effective methods during the course of the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of the ulcer extending to the underlying muscle, tendon, or bone;
  2. Diabetes mellitus that has to be confirmed by blood test ( >7.5%);
  3. Peripheral Artery Disease including claudication with need of treatment;
  4. Acute deep vein thrombosis (maximum 30 days from diagnosis) or a still untreated deep vein thrombosis;
  5. Unable to tolerate leg ulcer compression bandage;
  6. Infection of the target ulcer requiring treatment as judged clinically;
  7. All diagnosed disorders, unrelated to CVU, that are influencing wound healing of the target wound at investigator's discretion;
  8. Current use of medications that influence wound healing: systemic immunosuppressives, cytotoxic medicinal products, and systemic (above Cushing-threshold level);
  9. Patient who, in the opinion of the investigator, for any reason are unable or unwilling to complete the trial per protocol (e.g. alcohol or substance abuse, not mobile, short ) or there is evidence of any other medical condition (such as psychiatric illness, physical examination, or laboratory findings) that may interfere with the planned treatment, affect the patient's compliance, or place the patient at high risk of complications related to the treatment;
  10. Any within the past 5 years, excluding successfully treated carcinoma in situ, basal cell carcinoma or squamous cell carcinoma of the skin without evidence of ;
  11. Pregnant or lactating women;
  12. Any known allergies to components of the IMP;
  13. Prior surgical procedures such as bypass or mesh-graft treatment at target leg within 2 months prior to Visit 1 at target leg;
  14. Patients with significant ulcer healing or wound size enlargement of more than 25% at Visit 2 compared to Visit 1;
  15. Treatment of target ulcer with active wound care agents (e.g. Iruxol®N), which have not been paused 14 days before IMP application;
  16. Current or previous (within 30 days of enrollment) treatment with another IMP, or participation and/or under follow-up in another clinical trial;
  17. Previous participation in this clinical trial (except for screening failures due to an inclusion or exclusion criterion);
  18. Employees of the sponsor, or employees or relatives of the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    allo-APZ2-CVU (dose group 1: 1 x 10e6 cells/cm²)

    Application of IMP on patients wound

    Biological: allo-APZ2-CVU

  • Placebo comparator
    Placebo

    Application of IMP on patients wound

    Drug: Placebo

  • Experimental
    allo-APZ2-CVU (dose group 2: 3 x 10e6 cells/cm²)

    Application of IMP on patients wound

    Biological: allo-APZ2-CVU

  • Experimental
    allo-APZ2-CVU (dose group 3: 6 x 10e6 cells/cm²)

    Application of IMP on patients wound

    Biological: allo-APZ2-CVU

Interventions

  • Biologicalallo-APZ2-CVU

    Suspension of ABCB5-positive dermal mesenchymal stromal cells. One topical application with a syringe.

    Also known as: Skin-derived ABCB5-positive dermal mesenchymal stromal cells

  • DrugPlacebo

    One topical application with a syringe

06

What researchers measure

Primary outcomes

  1. Complete wound closure at Week 18 already persisting for at least two weeks

    Complete wound closure at Week 18 already persisting for at least two weeks will be evaluated.

    Time frame: Week 18

  2. Assessment of adverse event (AE) occurrence

    All AEs occurring during the clinical trial will be registered, documented and evaluated.

    Time frame: Up to 10 months

Secondary outcomes

  1. Wound size change in percent at each post-baseline follow-up visit

    Wound size change in percent at each post-baseline follow-up visit will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  2. Time to complete wound closure

    Time to complete wound closure will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  3. Complete wound closures at each post-baseline follow-up visit

    Complete wound closures at each post-baseline follow-up visit will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10, Month 16

  4. Duration of wound closure

    Duration of wound closure will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  5. Recurrence of the wound

    Recurrence of the wound will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10, Month 16

  6. Quality of wound healing (wound exudate) at each post-baseline follow-up visit

    The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the amount and type of wound exudate.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10, Month 16

  7. Quality of wound healing (granulation tissue together with epithelialization) at each post-baseline follow-up visit

    The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the formation of granulation tissue together with epithelialization.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  8. Quality of wound healing (scar formation) at each post-baseline follow-up visit

    The Quality of wound healing will be assessed at each post-baseline follow-up visit on the basis of the questions regarding scar formation.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  9. Assessment of Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14, V15, V16

    Quality of Life using the Wound-Quality of Life Questionnaire at V8, V11, V14, V15, V16 will be evaluated.

    Time frame: Week 6, 12, 18, Month 6 and 10

  10. Pain assessment as per numerical rating scale on each post-baseline follow-up visit

    Pain assessment as per numerical rating scale on each post-baseline follow-up visit will be evaluated.

    Time frame: Day 1-2, Week 1, 2, 4, 6, 8, 10, 12, 14, 16, Month 6 and 10

  11. Physical examination and vital signs at V14

    A physical body examination (e.g. general appearance, thyroid, head, lungs and thorax, ears, cardiovascular system, eyes, abdomen, nose-mouth-throat, musculoskeletal system, skin, extremities, lymph nodes, neurological system) will be performed and abnormal physical examination results will be evaluated and reported as AEs.

    Time frame: Week 18

07

Study locations

38 sites
  • MVZ Gefäßzentrum Aachen am Marienhospital Aachen GmbH
    Aachen, 52066, Germany
  • Universitätsklinikum Augsburg, Klinik für Dermatologie und Allergologie, Campus Süd
    Augsburg, 86179, Germany
  • Fachklinik Bad Bentheim, Dermatologische Ambulanz
    Bad Bentheim, 48455, Germany
  • Helios Klinikum Berlin-Buch, Klinik für Plastische und Ästhetische Chirurgie
    Berlin, 13125, Germany
  • Helios Klinikum Emil von Behring, Klinik für Plastische und Ästhetische Chirurgie
    Berlin, 14165, Germany
  • Hautarztpraxis Dr. Niesmann & Dr. Othlinghaus, Hautzentrum im Jahrhunderthaus
    Bochum, 44793, Germany
  • Katholisches Klinikum Bochum gGmbH, Venenzentrum der Kliniken für Dermatologie und Gefäßchirurgie der Ruhr-Universität Bochum
    Bochum, 44805, Germany
  • Hautärzte Braunschweig am Altstadtmarkt, Hautärztliche Gemeinschaftspraxis
    Braunschweig, 38100, Germany
  • Klinikum Bremerhaven Reinkenheide gGmbH, Klinik für Dermatologie, Allergologie und Phlebologie, Wundzentrum
    Bremerhaven, 27574, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • Universitätsklinikum Erlangen, Hautklinik - Wundzentrum Dermatologie
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
    Essen, 45147, Germany
  • Universitätsklinikum Freiburg, Klinik für Dermatologie und Venerologie
    Freiburg im Breisgau, 79104, Germany
  • Marienhospital Gelsenkirchen GmbH, Klinik für Chirurgie (Allgemein-, Viszeral- und Endokrine Chirurgie, Thorax-, Gefäß- und Endovaskuläre Chirurgie und Kinderchirurgie)
    Gelsenkirchen, 45886, Germany
  • SRH Wald-Klinikum Gera GmbH, Zentrum für Klinische Studien
    Gera, 07548, Germany
  • Universitätsmedizin Greifswald, Klinik und Poliklinik für Hautkrankheiten
    Greifswald, 17475, Germany
  • Praxis Dr. med. Abdou Zarzour
    Halle, 06108, Germany
  • Universitätsklinikum Hamburg- Eppendorf, Institut für Versorgungsforschung in der Dermatologie und bei Pflegeberufen (IVDP)
    Hamburg, 20246, Germany
  • MVZ Prof. Dr. Ockenfels, Haut und Allergie-Praxisklinik GmbH
    Hanau, 63450, Germany
  • Klinikum Region Hannover GmbH, KRH Klinikum Siloah, Klinik für Nephrologie, Angiologie und Rheumatologie
    Hanover, 30459, Germany
  • Zentrum für Dermatochirurgie, St. Josefskrankenhaus Heidelberg GmbH
    Heidelberg, 69115, Germany
  • SRH Klinikum Karlsbad- Langensteinbach GmbH, Interdisziplinäres Gefäßzentrum Innere Medizin
    Karlsbad, 76307, Germany
  • Medizinisches Versorgungszentrum DermaKiel GmbH
    Kiel, 24148, Germany
  • Hautarztpraxis Langenau, Studienzentrum
    Langenau, 89129, Germany
  • Universitätsklinikum Leipzig AöR, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
    Leipzig, 04103, Germany
  • Diabetologikum Ludwigshafen, die Praxis am Ludwigsplatz
    Ludwigshafen, 67059, Germany
  • Beldio Research GmbH
    Memmingen, 87700, Germany
  • Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Dermatologie und Allergologie
    München, 80337, Germany
  • Universitätsklinikum Münster, Klinik für Hautkrankheiten, Allgemeine Dermatologie und Venerologie
    Münster, 48149, Germany
  • Klinikum Nürnberg Nord, Klinik für Dermatologie
    Nuremberg, 90419, Germany
  • MVZ Corius Potsdam GmbH, Dermatologie Potsdam MVZ
    Potsdam, 14467, Germany
  • Caritas-Krankenhaus St. Josef, Klinik für Plastische und Ästhetische, Hand- und Wiederherstellungschirurgie
    Regensburg, 93053, Germany
  • Universitätsmedizin Rostock, Klinik und Poliklinik für Dermatologie und Venerologie
    Rostock, 18057, Germany
  • Helios Kliniken Schwerin, Plastische, Rekonstruktive und Ästhetische Chirurgie
    Schwerin, 19049, Germany
  • Hautärztliche Gemeinschaftspraxis Dr. Leitz und Kollegen
    Stuttgart, 70178, Germany
  • Universitätsklinikum Tübingen, Universitäts-Hautklinik Tübingen
    Tübingen, 72076, Germany
  • Helios Universitätsklinikum Wuppertal, Zentrums für Dermatologie, Allergologie und Dermatochirurgie
    Wuppertal, 42283, Germany
  • Universitätsklinikum Würzburg, Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie
    Würzburg, 97080, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Nov 2025, 51 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2021
First posted
Jul 21, 2021
StartActual
Aug 18, 2021
Primary completionActual
Nov 25, 2025
CompletionActual
Nov 25, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04971161
Lead sponsor
RHEACELL GmbH & Co. KG
Collaborators
FGK Clinical Research GmbH
Responsible party
Sponsor
First posted
Jul 21, 2021
Start date
Aug 18, 2021
Primary completion
Nov 25, 2025
Completion
Nov 25, 2025
Last update
Dec 4, 2025

Study contacts

Andreas Kerstan, Dr.
principal investigator · Klinik und Poliklinik für Dermatologie, Venerologie und Allergologie, Würzburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion